Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
Primary result · Disease flareResult — go to the resultRisk difference 58% 95% CI 42%–74%Authors' conclusion
In patients with RA in remission for more than 1 year while using TNFi, an increase in flare rate was reported in those who tapered TNFi to discontinuation.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in remission ≥12 months on stable TNFi, nine Norwegian rheumatology departments84 per-protocol
- Participants
- 99 patients
- Comparison
- Tapering TNFi to discontinuation vs stable TNFi
- Tapering TNFin = 43
- Stable TNFin = 41reference
- Primary endpoint
- Disease flare during the 12-month study period (non-inferiority margin 20%), per-protocol population
- Follow-up
- 12 months
Methodological detailsopen-label, non-inferiority, multicentre, block-randomisation, June 2013 to January 2019; 92 received allocated strategy
- Open-label
- Non-inferiority
- Multicentre
- Block-randomisation
- June 2013 to January 2019; 92 received allocated strategy
Primary result
Disease flare
Risk difference
58%
95% CI 42%–74%
Events by treatment group
Tapering TNFivs Stable TNFi
risk difference 58% (95% CI 42%–74%)
As reported in the abstract
Safety
| Outcome | Tapering TNFi | Stable TNFi |
|---|---|---|
| Total/serious adverse events (number) | 49/3 events | 57/2 events |
Original publication
Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →